Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Li, Xiaofeng; He, Yinghui; Zhu, Jinfeng; Pang, Hongxia; Lin, Yongwei; Zheng, Jinyang

doi:10.18632/oncotarget.25989

Cited by 13 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD-L1 expression was noted in 44.4% and 12.0% of mutant and wild-type KRAS genes, respectively ( 21 ). Therapies targeting several genes, including EGFR-TKI ( 13 , 22 , 23 ), ALK-TKIs ( 24 ), MET-TKIs ( 25 ), antiangiogenic therapy ( 26 , 27 ) and immune-checkpoint inhibitors ( 21 , 28 ), were tested in patients with PSC, although given the rarity of the tumor type, large scale studies of any particular therapy may never be completed.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

et al. 2022

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small-cell lung cancer (NSCLC). Here, we present information on the clinicopathologic characteristics and clinical outcomes of this type of cancer. Clinicopathologic data from 55 patients treated at a single cancer center from January 2011 to December 2018 were retrospectively analyzed. The patients were mostly male (76.4%), with a median age of 66 years and a history of smoking (54.5%). Most had symptoms, and about 60% presented with locally advanced or metastatic disease at diagnosis. Of the 55 cases, 21 were diagnosed by surgical resection. Pleomorphic cancer was the most common subtype (58.1%). With a median follow-up period of 13.2 months, the average survival time of the patients was 16.1 months, and the median survival time was 12 months. The overall survival rates for 1, 2, and 3 years were 52.7%, 18.2%, and 9.1%, respectively. Univariate analysis showed that prognosis of the patients was influenced by tumor size, T stage, metastatic status, and surgery (p < 0.05). Multivariate analysis showed that T stage (p = 0.034) was an independent prognostic factor. There are few reports on the natural history of PSC, and its clinicopathological characteristics remain unclear. Herein, a retrospective review 55 individuals with PSC found that T stage was an independent predictor of survival. Surgical resection was associated with better prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Surprisingly, there were no evident complications associated with apatinib. 79 Li et al reported a case in which the patient was administered apatinib (250 mg) orally once per day. Sustained tumor regression was observed after treatment, and no severe complications were reported to be associated with apatinib therapy.…”

Section: Targeted Therapymentioning

confidence: 99%

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Liu

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 ( EGFR/VEGFR2), anaplastic lymphoma kinase ( ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 ( PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.

show abstract

“…According to the Li et al , one PSC patient treated with apatinib, a TKI that selectively targets VEGFR2 expression in tumor cells, showed sustained tumor regression after treatment. No severe complications are associated with apatinib therapy ( 24 ). Patients with post-operative recurrent PSC treated with anlotinib combined with chemotherapy (dacarbazine and cisplatin) have also achieved CR ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review

Piao¹,

Ma²,

Tankere³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare disease which is highly malignant with a poor prognosis. PSC is highly resistant to chemotherapy and radiotherapy and is prone to recurrence even after surgery. Most of what is known about PSC comes from limited single-center, retrospective studies.There is still no standard international clinical guideline for PSC. Limited case reports have shown that PSC patients with driver gene mutations and high programmed death-ligand 1 (PD-L1) expression have good responses to molecular targeted therapy and immune checkpoint inhibitor (ICI) immunotherapy, respectively. Therefore, current first-line chemotherapy, targeted therapy and immunotherapy play a leading role in the diagnosis and treatment of advanced PSC patients.Case Description: We report a 42-year-old male who was diagnosed with PSC [stage IVB (T4N2M1)] and treated at our department (

show abstract

Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Cited by 13 publications

References 30 publications

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review

Contact Info

Product

Resources

About